Passier Robert, van Laake Linda W, Mummery Christine L
Hubrecht Institute, Developmental Biology and Stem Cell Research, Uppsalalaan 8, 3584 CT Utrecht, The Netherlands.
Nature. 2008 May 15;453(7193):322-9. doi: 10.1038/nature07040.
The potential usefulness of human embryonic stem cells for therapy derives from their ability to form any cell in the body. This potential has been used to justify intensive research despite some ethical concerns. In parallel, scientists have searched for adult stem cells that can be used as an alternative to embryonic cells, and, for the heart at least, these efforts have led to promising results. However, most adult cardiomyocytes are unable to divide and form new cardiomyocytes and would therefore be unable to replace those lost as a result of disease. Basic questions--for example, whether cardiomyocyte replacement or alternatives, such as providing the damaged heart with new blood vessels or growth factors to activate resident stem cells, are the best approach--remain to be fully addressed. Despite this, preclinical studies on cardiomyocyte transplantation in animals and the first clinical trials with adult stem cells have recently been published with mixed results.
人类胚胎干细胞在治疗方面的潜在用途源于它们能够形成体内任何细胞的能力。尽管存在一些伦理问题,但这种潜力已被用于为深入研究提供正当理由。与此同时,科学家们一直在寻找可作为胚胎细胞替代物的成体干细胞,至少对于心脏而言,这些努力已取得了有希望的成果。然而,大多数成体心肌细胞无法分裂并形成新的心肌细胞,因此无法替代因疾病而损失的心肌细胞。一些基本问题——例如,心肌细胞替代或其他替代方法,如为受损心脏提供新血管或生长因子以激活驻留干细胞,哪种是最佳方法——仍有待充分探讨。尽管如此,最近已发表了关于动物心肌细胞移植的临床前研究以及成体干细胞的首次临床试验,结果喜忧参半。